Nuformix plc

LVRT

GB00BYW79Y38

Pharmaceuticals

Delayed London S.E. Other stock markets 07:49:58 04/07/2024 pm IST			5-day change	1st Jan Change
0.1608 ^GBX	-8.11%		-5.41%	-50.52%

18/06	Nuformix shares fall despite interim loss narrowing	AN
18/06	Nuformix plc Reports Earnings Results for the Half Year Ended March 31, 2024	CI

Nuformix Announces Resignation of Dave Tapolczay as Non-Executive Chairman of the Board of Directors

February 05, 2020 at 10:16 pm IST

Nuformix announced the resignation of Dave Tapolczay as non-executive Chairman of the company board of directors with immediate effect.

Latest news about Nuformix plc

Nuformix shares fall despite interim loss narrowing	18/06	AN
Nuformix plc Reports Earnings Results for the Half Year Ended March 31, 2024	18/06	CI
Nuformix Secures New EU, US Patents for Development Programs	17/06	MT
Nuformix touts patent wins for idiopathic pulmonary fibrosis treatment	17/06	AN
Nuformix plc Announces Patent Update	17/06	CI
Nuformix announces subscription to raise GBP150,000	01/03	AN
Nuformix plc Reports Earnings Results for the Eighteen Months Ended September 30, 2023	15/01	CI
Nuformix narrows annual loss as develops drug assets	03/01	AN
Earnings Flash (NFX.L) NUFORMIX Reports FY23 Loss GBX-0.12	03/01	MT
Nuformix plc Reports Earnings Results for the Eighteen Months Ended September 30, 2023	03/01	CI
Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002	23/23/23	AN
Nuformix Receives Japanese Patent for Pulmonary Fibrosis Treatment; Shares Surge	23/23/23	MT
Nuformix plc Announces Notice of Allowance of NXP002 Patent in Japan	23/23/23	CI
Nuformix Updates Oxilio Agreement for NXP001	18/23/18	MT
Nuformix to receive milestone payments from Oxilio pact	18/23/18	AN
Nuformix plc Receives New NXP001 Development Milestone Payments in Updated Oxilio Agreement	18/23/18	CI
Nuformix loss narrows; near-term goal to focus on NXP002 asset	22/23/22	AN
Earnings Flash (NFX.L) NUFORMIX Posts FY23 EPS GBX0.11	22/23/22	MT
Earnings Flash (NFX.L) NUFORMIX Posts Fiscal H1 EPS GBX0.11	22/23/22	MT
Nuformix plc Reports Earnings Results for the Full Year Ended March 31, 2023	22/23/22	CI
Nuformix says NXP002 shows anti-inflammatory effect	18/23/18	AN
Nuformix to Launch Partnering Process for Inhaled Lung Disease Drug	18/23/18	MT
Nuformix plc Announces Update Regarding the NXP002 Programme	18/23/18	CI
FTSE 100 Inches Up as Market Awaits Key Inflation, Earnings Figures	17/23/17	DJ
UK Inflation Likely Dropped Below Double Digits in March	17/23/17	DJ

Nuformix plc is a United Kingdom-based pharmaceutical development company. The Company is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing, and patenting novel drug forms, with improved physical properties, to develop new products that are differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001 is pursuing licensing opportunities. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation.

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NUFORMIX PLC	-50.52%	18.3L
ELI LILLY AND COMPANY	+54.07%	81TCr
NOVO NORDISK A/S	+39.16%	62TCr
JOHNSON & JOHNSON	-7.05%	35TCr
MERCK & CO., INC.	+15.44%	32TCr
ABBVIE INC.	+5.72%	29TCr
ASTRAZENECA PLC	+14.28%	24TCr
ROCHE HOLDING AG	-0.61%	22TCr
NOVARTIS AG	+14.62%	22TCr
AMGEN INC.	+7.42%	17TCr

Other Pharmaceuticals

Nuformix plc

Equities

LVRT

GB00BYW79Y38

Pharmaceuticals

Nuformix Announces Resignation of Dave Tapolczay as Non-Executive Chairman of the Board of Directors

Latest news about Nuformix plc

Chart Nuformix plc

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals